RT Journal Article
T1 Polymeric Nanoparticles and Chitosan Gel Loading Ketorolac Tromethamine to Alleviate Pain Associated with Condyloma Acuminata during the Pre- and Post-Ablation.
A1 El Moussaoui, Salima
A1 Abo-Horan, Ismael
A1 Halbaut, Lyda
A1 Alonso, Cristina
A1 Coderch, Lluïsa
A1 Garduño-Ramírez, María Luisa
A1 Clares, Beatriz
A1 Soriano, José Luis
A1 Calpena, Ana Cristina
A1 Fernández-Campos, Francisco
A1 Mallandrich, Mireia
K1 Condyloma acuminata
K1 PLGA nanoparticles
K1 anti-inflammatory
K1 chitosan gel
K1 ketorolac tromethamine
K1 topical delivery
AB This study describes the preparation and evaluation of two formulations, a hydrogel and a nanostructured system, containing ketorolac tromethamine as an anti-inflammatory agent for the local therapy against the inflammatory process derived from the surgical excision of Condyloma acuminata. Both formulations were physicochemically characterized. In vitro release profiles show that the nanoparticles release 92% ± 2.3 of the total ketorolac tromethamine encapsulated, while the chitosan gel releases 18.6% ± 0.2. The ex vivo permeation and distribution through human skin were also assayed and was observed how the main amount of ketorolac tromethamine is retained in the epidermis. In vivo studies were accomplished to evaluate the anti-inflammatory efficacy in mice which also involved the histological analysis to confirm the in vivo results. The nanoparticles present a significantly higher anti-inflammatory efficacy than chitosan gel. The tolerability of developed formulations was assessed by monitoring the biomechanical properties of the skin before and after application of both formulations. No statistical differences in trans-epidermal water loss and skin hydration with respect to the basal values were observed and the formulations exhibited higher anti-inflammatory activity compared to a reference ketotorlac tromethamine solution. Therefore, it can be concluded that both formulations can be proposed as outstanding candidates for offering a local anti-inflammatory therapeutical tool with potential clinical application.
SN 1999-4923
YR 2021
FD 2021-10-25
LK https://hdl.handle.net/10668/26110
UL https://hdl.handle.net/10668/26110
LA en
DS RISalud
RD Apr 5, 2025